Pancreatic cancer is resistant to almost all cytotoxic drugs. Currently, gemcitabine appears
to be the only clinically active drug but, because of pre-existing or acquired chemoresistance …

Purpose: Hypoxia, frequently found in the center of solid tumor, is associated with resistance
to chemotherapy by activation of signaling pathways that regulate cell pro-liferation …

Human pancreatic adenocarcinoma cell lines PK1 and PK8 are resistant to the clinically
relevant chemotherapy agent gemcitabine. Cell cycle analysis demonstrated an …

Objectives: Resistance to chemotherapy is a major cause of treatment failure and poor
prognosis in pancreatic cancer. Inasmuch as most effects of chemotherapeutic agents are …

Purpose: Nuclear factor κB (NFκB) activity may increase survival and protect cancer cells
from chemotherapy. Therefore, NFκB activity may be prognostic, and inhibition of NFκB may …

The transcription factor NF-κB has anti-apoptotic properties and may confer
chemoresistance to cancer cells. Here, we describe human pancreatic carcinoma cell lines …

Except for gemcitabine, chemotherapeutic agents are ineffective with pancreatic
adenocarcinoma because this cancer is resistant to apoptosis induction. Involvement of …

The diagnosis of pancreatic cancer confers a grim prognosis that has changed little over the
last 30 years. Due to the lack of any efficacious screening or biomarkers for pancreatic …

Purpose: Although chemotherapy with gemcitabine is a common mode of treatment of
pancreatic cancer, 75% of patients do not benefit from this therapy. It is likely that the …

BACKGROUND: Chemoresistance is an important clinical problem in pancreatic cancer. As
the mitogen-activated protein kinases (MAPKs) have been found to be involved in the …